Anxiety Disorders - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 278 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anxiety Disorders - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Anxiety Disorders - Pipeline Review, H1 2015', provides an overview of the Anxiety Disorders's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anxiety Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anxiety Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anxiety Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Anxiety Disorders Overview 10
Therapeutics Development 11
Pipeline Products for Anxiety Disorders - Overview 11
Pipeline Products for Anxiety Disorders - Comparative Analysis 12
Anxiety Disorders - Therapeutics under Development by Companies 13
Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes 17
Anxiety Disorders - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Anxiety Disorders - Products under Development by Companies 23
Anxiety Disorders - Products under Investigation by Universities/Institutes 29
Anxiety Disorders - Companies Involved in Therapeutics Development 31
AbbVie Inc. 31
Ache Laboratorios Farmaceuticos S/A 32
Adamed Sp. z o.o. 33
Addex Therapeutics Ltd 34
Avineuro Pharmaceuticals, Inc. 35
Azevan Pharmaceuticals, Inc. 36
Beech Tree Labs, Inc. 37
Bionomics Limited 38
Boehringer Ingelheim GmbH 39
C4X Discovery Ltd 40
Catalyst Pharmaceutical Partners, Inc. 41
Concert Pharmaceuticals, Inc. 42
Edgemont Pharmaceuticals, LLC 43
Eisai Co., Ltd. 44
Eli Lilly and Company 45
F. Hoffmann-La Roche Ltd. 46
GW Pharmaceuticals plc 47
H. Lundbeck A/S 48
Heptares Therapeutics Ltd. 49
HolsboerMaschmeyer NeuroChemie GmbH 50
Humanetics Corporation 51
Intra-Cellular Therapies, Inc. 52
Johnson & Johnson 53
Marinus Pharmaceuticals, Inc. 54
Merz Pharmaceuticals GmbH 55
MI.TO. Technology S.r.L. 56
Nanotherapeutics, Inc. 57
Neuralstem, Inc. 58
Neurocrine Biosciences, Inc. 59
NeuroNascent, Inc. 60
Newron Pharmaceuticals S.p.A. 61
Novartis AG 62
Nuvo Research Inc. 63
Omeros Corporation 64
Otsuka Holdings Co., Ltd. 65
Pfizer Inc. 66
Polleo Pharma Limited 67
Rottapharm SpA 68
Sellas Inc. 69
SK Biopharmaceuticals Co., Ltd. 70
Suda Ltd 71
Sumitomo Dainippon Pharma Co., Ltd. 72
Tonix Pharmaceuticals Holding Corp. 73
Trevena, Inc. 74
Vanda Pharmaceuticals Inc. 75
Anxiety Disorders - Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Target 77
Assessment by Mechanism of Action 81
Assessment by Route of Administration 84
Assessment by Molecule Type 86
Drug Profiles 88
7-Keto - Drug Profile 88
ADN-2013 - Drug Profile 89
ADX-71441 - Drug Profile 90
ADX-71743 - Drug Profile 91
ADX-88178 - Drug Profile 92
alprazolam - Drug Profile 93
AVL-5189 - Drug Profile 94
AVN-101 - Drug Profile 95
AVN-397 - Drug Profile 96
AVN-628 - Drug Profile 97
AZ-01 - Drug Profile 98
BCA-909 - Drug Profile 99
bitopertin - Drug Profile 101
BNC-210 - Drug Profile 103
brexpiprazole - Drug Profile 105
BTL-ng - Drug Profile 107
CPP-115 - Drug Profile 108
CR-5542 Series - Drug Profile 110
CTP-354 - Drug Profile 111
dipraglurant IR - Drug Profile 112
Drug for Post-Traumatic Stress Disorders - Drug Profile 113
Drugs to Activate HAT for CNS Disorders - Drug Profile 114
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 115
Drugs to Inhibit Histone Deacetylase for CNS Disorders - Drug Profile 116
Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile 117
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 118
E-2508 - Drug Profile 119
EDG-008 - Drug Profile 120
fluvoxamine maleate - Drug Profile 121
ganaxolone - Drug Profile 122
iloperidone - Drug Profile 124
ITI-007 - Drug Profile 126
itriglumide - Drug Profile 128
JNJ-31020028 - Drug Profile 129
JNJ-42165279 - Drug Profile 130
lorazepam ER - Drug Profile 131
LSN-2535717 - Drug Profile 132
LY-2607540 - Drug Profile 133
mavoglurant - Drug Profile 134
methoxycoronaridine - Drug Profile 136
midazolam hydrochloride - Drug Profile 137
MRZ-8676 - Drug Profile 138
nabiximols - Drug Profile 139
NB-51R1 - Drug Profile 142
NNI-351 - Drug Profile 143
NSI-189 - Drug Profile 144
NTC-942 - Drug Profile 145
NW-3509 - Drug Profile 146
OMS-527 - Drug Profile 147
Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile 148
Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - Drug Profile 149
PF-06372865 - Drug Profile 150
PT-00114 - Drug Profile 151
PT-00121 - Drug Profile 152
PT-00211 - Drug Profile 153
PT-00411 - Drug Profile 154
Ro-646198 - Drug Profile 155
Rycal - Drug Profile 156
S-107 - Drug Profile 157
SCT-66 - Drug Profile 158
Small Molecule to Agonize mGluR2 for Anxiety Disorders - Drug Profile 159
Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile 160
Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile 161
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 162
Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders - Drug Profile 163
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 165
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 166
Small Molecules for BED and PTSD - Drug Profile 167
Small Molecules for Depression and Anxiety - Drug Profile 168
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 169
Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile 170
Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile 171
Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 172
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 173
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 174
Small Molecules to Agonize Mineralocorticoid Receptor for Depression and Anxiety - Drug Profile 175
Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile 176
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 177
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 178
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 179
Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders - Drug Profile 180
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 181
Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 182
SRX-246 - Drug Profile 183
SRX-251 - Drug Profile 185
Synthetic Peptide for Anxiety Disorders - Drug Profile 187
tedatioxetine - Drug Profile 188
TNX-102 - Drug Profile 190
TPI-136117 - Drug Profile 192
TRV-250 - Drug Profile 193
UCM-765 - Drug Profile 194
Vaccine for Post-Traumatic Stress Disorder and Depression - Drug Profile 195
VAD-1 - Drug Profile 196
VAD-2 - Drug Profile 197
verucerfont - Drug Profile 198
vigabatrin - Drug Profile 200
vortioxetine hydrobromide - Drug Profile 203
YKP-3089 - Drug Profile 206
ZL-006 - Drug Profile 208
zolpidem tartrate - Drug Profile 209
Anxiety Disorders - Recent Pipeline Updates 210
Anxiety Disorders - Dormant Projects 246
Anxiety Disorders - Discontinued Products 258
Anxiety Disorders - Product Development Milestones 263
Featured News & Press Releases 263
Appendix 270
Methodology 270
Coverage 270
Secondary Research 270
Primary Research 270
Expert Panel Validation 270
Contact Us 270
Disclaimer 271

List of Tables
Number of Products under Development for Anxiety Disorders, H1 2015 18
Number of Products under Development for Anxiety Disorders - Comparative Analysis, H1 2015 19
Number of Products under Development by Companies, H1 2015 20
Number of Products under Development by Companies, H1 2015 (Contd..1) 21
Number of Products under Development by Companies, H1 2015 (Contd..2) 22
Number of Products under Development by Companies, H1 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2015 25
Comparative Analysis by Late Stage Development, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Development, H1 2015 28
Comparative Analysis by Unknown Stage Development, H1 2015 29
Products under Development by Companies, H1 2015 30
Products under Development by Companies, H1 2015 (Contd..1) 31
Products under Development by Companies, H1 2015 (Contd..2) 32
Products under Development by Companies, H1 2015 (Contd..3) 33
Products under Development by Companies, H1 2015 (Contd..4) 34
Products under Development by Companies, H1 2015 (Contd..5) 35
Products under Investigation by Universities/Institutes, H1 2015 36
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 37
Anxiety Disorders - Pipeline by AbbVie Inc., H1 2015 38
Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 39
Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H1 2015 40
Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H1 2015 41
Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2015 42
Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 43
Anxiety Disorders - Pipeline by Beech Tree Labs, Inc., H1 2015 44
Anxiety Disorders - Pipeline by Bionomics Limited, H1 2015 45
Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H1 2015 46
Anxiety Disorders - Pipeline by C4X Discovery Ltd, H1 2015 47
Anxiety Disorders - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 48
Anxiety Disorders - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 49
Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015 50
Anxiety Disorders - Pipeline by Eisai Co., Ltd., H1 2015 51
Anxiety Disorders - Pipeline by Eli Lilly and Company, H1 2015 52
Anxiety Disorders - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 53
Anxiety Disorders - Pipeline by GW Pharmaceuticals plc, H1 2015 54
Anxiety Disorders - Pipeline by H. Lundbeck A/S, H1 2015 55
Anxiety Disorders - Pipeline by Heptares Therapeutics Ltd., H1 2015 56
Anxiety Disorders - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2015 57
Anxiety Disorders - Pipeline by Humanetics Corporation, H1 2015 58
Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 59
Anxiety Disorders - Pipeline by Johnson & Johnson, H1 2015 60
Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 61
Anxiety Disorders - Pipeline by Merz Pharmaceuticals GmbH, H1 2015 62
Anxiety Disorders - Pipeline by MI.TO. Technology S.r.L., H1 2015 63
Anxiety Disorders - Pipeline by Nanotherapeutics, Inc., H1 2015 64
Anxiety Disorders - Pipeline by Neuralstem, Inc., H1 2015 65
Anxiety Disorders - Pipeline by Neurocrine Biosciences, Inc., H1 2015 66
Anxiety Disorders - Pipeline by NeuroNascent, Inc., H1 2015 67
Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H1 2015 68
Anxiety Disorders - Pipeline by Novartis AG, H1 2015 69
Anxiety Disorders - Pipeline by Nuvo Research Inc., H1 2015 70
Anxiety Disorders - Pipeline by Omeros Corporation, H1 2015 71
Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 72
Anxiety Disorders - Pipeline by Pfizer Inc., H1 2015 73
Anxiety Disorders - Pipeline by Polleo Pharma Limited, H1 2015 74
Anxiety Disorders - Pipeline by Rottapharm SpA, H1 2015 75
Anxiety Disorders - Pipeline by Sellas Inc., H1 2015 76
Anxiety Disorders - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 77
Anxiety Disorders - Pipeline by Suda Ltd, H1 2015 78
Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 79
Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 80
Anxiety Disorders - Pipeline by Trevena, Inc., H1 2015 81
Anxiety Disorders - Pipeline by Vanda Pharmaceuticals Inc., H1 2015 82
Assessment by Monotherapy Products, H1 2015 83
Number of Products by Stage and Target, H1 2015 86
Number of Products by Stage and Mechanism of Action, H1 2015 89
Number of Products by Stage and Route of Administration, H1 2015 92
Number of Products by Stage and Molecule Type, H1 2015 94
Anxiety Disorders Therapeutics - Recent Pipeline Updates, H1 2015 217
Anxiety Disorders - Dormant Projects, H1 2015 253
Anxiety Disorders - Dormant Projects (Contd..1), H1 2015 254
Anxiety Disorders - Dormant Projects (Contd..2), H1 2015 255
Anxiety Disorders - Dormant Projects (Contd..3), H1 2015 256
Anxiety Disorders - Dormant Projects (Contd..4), H1 2015 257
Anxiety Disorders - Dormant Projects (Contd..5), H1 2015 258
Anxiety Disorders - Dormant Projects (Contd..6), H1 2015 259
Anxiety Disorders - Dormant Projects (Contd..7), H1 2015 260
Anxiety Disorders - Dormant Projects (Contd..8), H1 2015 261
Anxiety Disorders - Dormant Projects (Contd..9), H1 2015 262
Anxiety Disorders - Dormant Projects (Contd..10), H1 2015 263
Anxiety Disorders - Dormant Projects (Contd..11), H1 2015 264
Anxiety Disorders - Discontinued Products, H1 2015 265
Anxiety Disorders - Discontinued Products (Contd..1), H1 2015 266
Anxiety Disorders - Discontinued Products (Contd..2), H1 2015 267
Anxiety Disorders - Discontinued Products (Contd..3), H1 2015 268
Anxiety Disorders - Discontinued Products (Contd..4), H1 2015 269